Literature DB >> 1860683

The metabolic bone disease of primary sclerosing cholangitis.

J E Hay1, K D Lindor, R H Wiesner, E R Dickson, R A Krom, N F LaRusso.   

Abstract

The incidence and severity of osteopenic bone disease in primary sclerosing cholangitis is poorly defined. Clinical, biochemical and radiographic assessment and bone mineral density measurements of the lumbar spine were carried out in two groups of patients. Group 1 consisted of 30 patients with advanced primary sclerosing cholangitis; group 2 consisted of 18 patients with newly diagnosed primary sclerosing cholangitis. Only one patient had bone pain. All patients were normocalcemic; two had elevated serum parathormone levels. Fourteen patients (47%) from group 1 but no patients from group 2 had low serum 25-hydroxyvitamin D levels. Mean bone mineral density was significantly reduced in group 1 patients (0.97 +/- 0.04 gm/cm2) compared with age-matched and sex-matched controls (1.25 +/- 0.01 gm/cm2, p less than 0.0001), and in 15 patients (50%) bone mineral density was below the fracture threshold (0.98 gm/cm2). The bone mineral density in group 2 was not significantly different from controls, and no patient was below the fracture threshold. In neither group did bone mineral density correlate with serum bilirubin, 25-hydroxyvitamin D, fecal fat excretion, previous drug therapy or the presence of chronic ulcerative colitis. Histomorphometrical examination of bone from four group 1 patients showed increased bone resorption, reduced bone formation, moderate-to-severe osteopenia and no osteomalacia. In conclusion, severe osteopenic bone disease is common in advanced primary sclerosing cholangitis and, like that seen in other cholestatis diseases, is consistent with osteoporosis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1860683

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  22 in total

Review 1.  Osteoporosis in chronic liver disease.

Authors:  J Heathcote
Journal:  Curr Gastroenterol Rep       Date:  1999-12

Review 2.  Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy.

Authors:  Thomas Pusl; Ulrich Beuers
Journal:  Clin Rev Allergy Immunol       Date:  2005-04       Impact factor: 8.667

3.  Patients, cells, and organelles: the intersection of science and serendipity.

Authors:  Nicholas F Larusso
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

4.  Diffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis: a comparison study with dual-energy X-ray absorptiometry.

Authors:  Sarah Keller; Harald Ittrich; Christoph Schramm; Ansgar W Lohse; Michael Amling; Gerhard Adam; Jin Yamamura
Journal:  Jpn J Radiol       Date:  2016-08-04       Impact factor: 2.374

5.  Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role?

Authors:  A Gaudio; A Lasco; N Morabito; M Atteritano; C Vergara; A Catalano; W Fries; A Trifiletti; N Frisina
Journal:  J Endocrinol Invest       Date:  2005-09       Impact factor: 4.256

6.  Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection.

Authors:  Ingolf Schiefke; Andreas Fach; Marcus Wiedmann; Andreas-V Aretin; Eva Schenker; Gudrun Borte; Manfred Wiese; Joachim Moessner
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

7.  Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss.

Authors:  J M Fernández-Real; F Ortega; J Gómez-Ambrosi; J Salvador; G Frühbeck; W Ricart
Journal:  Osteoporos Int       Date:  2010-03-04       Impact factor: 4.507

Review 8.  Metabolic bone disease in patients with liver disease.

Authors:  Elizabeth Carey; Vijayan Balan
Journal:  Curr Gastroenterol Rep       Date:  2003-02

Review 9.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Role of hyperbilirubinemia in the impairment of osteoblast proliferation associated with cholestatic jaundice.

Authors:  C H Janes; E R Dickson; R Okazaki; S Bonde; A F McDonagh; B L Riggs
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.